Psoriasis is an inflammatory skin disorder that affects about1 to 3 percent of persons throughout the world.1 Although mostpersons with plaque psoriasis have mild or moderate diseasethat affects small areas of the skin, some have extensive diseasethat is severe and difficult to treat. It is not known why somepersons have severe disease and others have mild involvement.
One theory of the pathogenesis of psoriasis is that it is primarilya disorder that involves the proliferation of keratinocytes,with secondary inflammation. Supporters of this concept havenoted defects in cytokine expression, intracellular signaling,and polyamines, as . . . [Full Text of this Article]
References
This article has been cited by other articles:
Hutmacher, M. M., Nestorov, I., Ludden, T., Zitnik, R., Banfield, C.
(2007). Modeling the Exposure-Response Relationship of Etanercept in the Treatment of Patients With Chronic Moderate to Severe Plaque Psoriasis. J Clin Pharmacol
47: 238-248
[Abstract][Full Text]
Schwartz, R. S.
(2003). Diversity of the Immune Repertoire and Immunoregulation. NEJM
348: 1017-1026
[Full Text]
Millard, T. P., Birch, K. E., Young, E. R., Haserick, J. R., Hanauer, L., Ellis, C. N., Krueger, G. G., Granstein, R. D.
(2001). Treatment of Plaque Psoriasis. NEJM
345: 1853-1855
[Full Text]
(2001). Alefacept Targets Memory Effector T Cells and Improves Psoriasis. Journal Watch Dermatology
2001: 3-3
[Full Text]
Previous
